Experimental and clinical study on ATP-MgCl2 administration for postischemic acute renal failure.
The present study was undertaken to investigate the effect of ATP-MgCl2 on the recovery of renal function following renal ischemia. Bilateral renal ischemia was produced for 90 minutes in dogs. Immediately after the release of ischemia, ATP-MgCl2 (50 mumoles/kg) was given intravenously. Serum creatinine and FeNa were measured following the release of ischemia. Renal cellular energy charge, glomerular endothelial thickness and per cent circularity of interstitial cells were measured. Creatinine and FeNa were significantly lower in ATP-MgCl2 treated dogs compared to those in saline treated controls. Changes in energy charge, glomerular endothelial thickness and per cent circularity indicated ischemically induced renal cellular edema was reversed with ATP-MgCl2 through the improvement of energy metabolism. Taking those experimental data into consideration, ATP-MgCl2 was given to 16 acute renal failure patients and 13 patients survived. ATP-MgCl2 administration is effective for the treatment of acute renal failure.
D058186:Acute Kidney Injury / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000818:Animals; D002675:Child, Preschool; D004285:Dogs; D005260:Female; D006801:Humans; D007511:Ischemia / Q000150:complications; D007668:Kidney / Q000098:blood supply / Q000473:pathology
D000255:Adenosine Triphosphate